This information is intended for members of the public and patients in the United Kingdom and Ireland only.

INFORMATION ON ZEPOSIA®▼ (OZANIMOD) FOR MEMBERS OF THE PUBLIC

This section contains reference information only. Bristol-Myers Squibb are unable to provide advice on personal medical matters. Please contact your doctor or other relevant healthcare professional for specific, health-related advice and support.

Zeposia contains the active substance ozanimod that belongs to a group of medicines which can reduce the number of white blood cells (lymphocytes) circulating freely round the body.

Please click here to access the ZEPOSIA (ozanimod) Summary of Product Characteristics and Patient Information Leaflet, which can be found on the electronic medicines compendium (eMC).

Report possible side effects (patients and members of the public in the UK or Ireland)
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly.
UK - see www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.
Ireland - via HPRA Pharmacovigilance at www.hpra.ie
Side effects should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK); 1 800 749 749 (Ireland)